<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04419454</url>
  </required_header>
  <id_info>
    <org_study_id>DO609568A</org_study_id>
    <nct_id>NCT04419454</nct_id>
  </id_info>
  <brief_title>Retrospective Evaluation of Cellulite of Laxity Treatment Using Body Tite</brief_title>
  <official_title>Retrospective Evaluation of Cellulite of Laxity Treatment Using Body Tite</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InMode MD Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InMode MD Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective Evaluation of Cellulite of Laxity Treatment Using Body Tite&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this preliminary report is to retrospectively evaluate this novel treatment&#xD;
      approach to improve the appearance of cellulite on the thighs and buttocks by tightening the&#xD;
      SFS using RFAL.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 5, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Photonumeric Cellulite Severity Score</measure>
    <time_frame>[ Time Frame: Baseline to 6 months posttreatment]</time_frame>
    <description>Change in Photonumeric Cellulite Severity Score 3. Investigator assessment of the cellulite improvement comparing pre and post treatment using Global aesthetic improvement 5-point grading scale (0=No change, 1=1%-24%%, 2=25%-49%, 3=50%-74% improvement, and 4=75%-100%) at all follow up visits.</description>
  </primary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Cellulite</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BodyTite</intervention_name>
    <description>retrospectively evaluate this novel treatment approach to improve the appearance of cellulite on the thighs and buttocks by tightening the SFS using RFAL.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Sample size will be a result of available charts from a 16-month retrospective review&#xD;
        January 2018 - May 2019. The sample will not include any vulnerable populations (pregnant&#xD;
        women, minors, or prisoners)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age â‰¥ 18years of age at the time of procedure&#xD;
&#xD;
               -  patients with localized lipodystrophy in the medial or lateral thigh, and visible&#xD;
                  cellulite of laxity in the lower extremity or buttocks&#xD;
&#xD;
               -  BodyTite treatments performed from January 2018 - May 2019 for Cellulite&#xD;
                  indication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  active infection, collagen disorders, immunocompromised state, medications that&#xD;
             mitigate inflammatory response, and propensity for keloid/hypertrophic scaring. o&#xD;
             BodyTite treatments performed from March 2018 - May 2019 for lipodystrophy and&#xD;
             cellulite of laxity&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Petrs, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Mark Peters</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 3, 2020</study_first_submitted>
  <study_first_submitted_qc>June 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2020</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cellulite</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

